<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01287286</url>
  </required_header>
  <id_info>
    <org_study_id>XMRPG890251</org_study_id>
    <nct_id>NCT01287286</nct_id>
  </id_info>
  <brief_title>Cancers Treated With Combination of Antrodia Cinnamomea and Chemotherapy</brief_title>
  <official_title>Cancers Treated With Combination of Antrodia Cinnamomea and Chemotherapy— a Double Blinded, Randomized, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>New Bellus Enterprises</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if food supplements,Antrodia cinnamomea, could
      minimize the gastrointestinal symptom of cancer patients with chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In our unpublished report shows that patients who took Antrodia Cinnamomea compound of 15
      milliliters liquid twice in a day, might help white blood cells, red blood cells and
      hemoglobin increase after 2 months; liver glutamic pyruvic transaminase(GPT) index
      mitigation, P &lt;0.05 difference statistically; In addition, liver glutamate oxaloacetate
      transaminase(GOT) and biochemical index of renal function had no abnormal data statistically.
      However, cancer patients with gastrointestinal disorders after chemotherapy is known to be a
      common side effect, we seek to investigate if Antrodia Cinnamomea improves the function of
      gastrointestinal system.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Anticipated">April 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastrointestinal symptoms in case group reduces 10% than control group during chemotherapy.</measure>
    <time_frame>1 month</time_frame>
    <description>Post-chemotherapy nausea, vomiting and epigastragia, etc. including gastrointestinal symptom/sign without mention above.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Life quality estimates of 10% improvement than control group.</measure>
    <time_frame>3 months</time_frame>
    <description>Life science related questionnairs visit 4 times just before treatment, after intervention 7 days, 30 days and 90 days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Neoplasm</condition>
  <condition>Functional Gastrointestinal Disorder</condition>
  <arm_group>
    <arm_group_label>AC-Can</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antrodia cinnamomea and concomitant chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and concomitant chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>AC-Can</intervention_name>
    <description>Antrodia cinnamomea compounds of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days</description>
    <arm_group_label>AC-Can</arm_group_label>
    <other_name>AC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed Cancer.

          -  Age ≦ 80 years old and ≧ 18 years old.

          -  Eastern Cooperative Oncology Group(ECOG) performance status of 0-2.

          -  Adequate organ function, including followings Hepatic： Total bilirubin level ≦1.5 x
             UNL, GOT and GPT ≦ 2.5 x UNL if no liver metastasis; GOT and GPT ≦ 5 x UNL if liver
             metastasis. Renal： Creatinine level＜ 1.5 milligram per deciliter or Estimated
             creatinine clearance(CCr) ≧ 60 milliliter per minute (CCr is estimated by
             Cockcroft-Gault formula, as appendix II)

          -  Estimated life expectancy of at least 12 weeks.

          -  Written(signed) Informed Consent

          -  Ever treated and poor tolerance with platinum-based or anthracycline- based regimen,
             likely nausea and vomiting.

        Exclusion Criteria:

          -  Prior participation in any investigational drug study within 28 days

          -  Active uncontrolled infections or human immunodeficiency virus(HIV) infection

          -  Significant concurrent medical diseases, such as congestive heart failure, unstable
             angina, acute or recent myocardial infarction( 6 months before randomization), chronic
             obstructive pulmonary disease with frequent exacerbation, chronic renal diseases
             (estimated CCr 60 milliliter per minute), uncontrolled diabetes, uncontrolled
             hypertension, recent cerebrovascular disease episode( 6 months before randomization )

          -  With clinically significant Gastrointestinal disorder (e.g. bleeding, inflammation,
             obstruction or diarrhea)

          -  Psychiatric disorders that would compromise the patient's compliance or decision.

          -  Pregnancy or breast feeding.

          -  Known hypersensitivity to the component of investigational drugs.

          -  Known or suspected Gilbert's syndrome

          -  Poor compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu-Chiang Hung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Traditional Chinese Medicine, Chang Gung Memorial Hospital - Kaohsiung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hsien-Hsueh E Chiu, MD</last_name>
    <phone>+887-7-7317123</phone>
    <phone_ext>2332</phone_ext>
    <email>elley@adm.cgmh.org.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Haematology and Oncology, Department of Internal Medicine and Traditional Chinese Medicine, Chang Gung Memorial Hospital - Kaohsiung Medical Center</name>
      <address>
        <city>Niaosong</city>
        <state>Kaohsiung</state>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pey-Harn Ywi-Chi, Bachelor</last_name>
      <phone>+886-7-7317123</phone>
      <phone_ext>2332</phone_ext>
      <email>kangta614@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Kun-Ming Rau, MD</last_name>
      <phone>+886-7-7317123</phone>
      <phone_ext>8303</phone_ext>
      <email>kmrau58@adm.cgmh.org.tw</email>
    </contact_backup>
    <investigator>
      <last_name>Hsien-Hsueh E Chiu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kun-Ming Rau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2011</study_first_submitted>
  <study_first_submitted_qc>January 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2011</study_first_posted>
  <last_update_submitted>February 6, 2011</last_update_submitted>
  <last_update_submitted_qc>February 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Yu-Chiang Hung / MD, PhD</name_title>
    <organization>Department of Traditional Chinese Medicine, Chang Gung Memorial Hospital- Kaohsiung Medical Center</organization>
  </responsible_party>
  <keyword>Cancers</keyword>
  <keyword>Antrodia cinnamomea</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Gastrointestinal Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

